#None #Innovent #SINTBILO #Tafolecimab

Innovent's SINTBILO™ Achieves Milestone in Treating Hyperlipidemia

Innovent Biologics, Inc. has recently announced significant results from its Phase 3 CREDIT-5 clinical trial, showcasing the promising effectiveness of SINTBILO™ (tafolecimab injection) as a monotherapy treatment for patients suffering from non-familial hypercholesterolemia and mixed hyperlipidemia. This milestone achievement marks a substantial breakthrough in lipid-lowering therapy, as the new drug demonstrated a powerful lipid-lowering efficacy alongside a favorable safety profile.

Study Overview

The multi-center, randomized, double-blind, placebo-controlled trial included 198 participants, divided into various groups receiving different dosages of SINTBILO™ or a placebo. After a comprehensive 12-week treatment period initiated after a 4-week run-in phase, results were evaluated to measure the primary endpoint: the percent change in low-density lipoprotein cholesterol (LDL-C) levels from baseline.

Key Findings

The data revealed impressive findings. Participants who received tafolecimab showed a mean LDL-C reduction of over 60% compared to those on a placebo. In particular, the 150 mg Q2W dosage exhibited a 65.19% decline in LDL-C versus a mere 6.61% in those receiving a placebo. Similarly, the 450 mg Q4W group recorded a 64.01% reduction compared to 4.31% in the placebo group, resulting in statistically compelling p-values of less than 0.0001.

The results didn't just stop at LDL-C measurements. Other lipid-related markers such as non-HDL-C, vLDL-C, ApoB, and lipoprotein(a) also showed significant improvements, reinforcing the treatment's potential to comprehensively manage blood lipid levels.

Safety Assessment

Safety was a critical component of this study. Throughout the trial, SINTBILO™ maintained a favorable safety profile with no new safety signals emerging. None of the adverse events (AEs) led to discontinuation of the treatment, indicating its tolerability among the participants. This is particularly noteworthy as it offers an alternative for patients historically intolerant to statins, which have dominated lipid-lowering therapies to date.

Implications for Patients and Clinicians

Professor Yida Tang, who led the study, pointed out the pressing need for effective non-statin treatment options in hyperlipidemia, where a number of patients may struggle with statin therapies due to intolerance or insufficient results. The successful outcomes of the CREDIT-5 trial provide strong clinical evidence supporting SINTBILO™ as a viable option for individuals not reaching their lipid targets with conventional therapies.

As Innovent prepares to submit a New Indication Application to the National Medical Products Administration in China, expectations grow for SINTBILO™ to become not only a revolutionary treatment in the Chinese market but also an accessible solution for millions of patients grappling with high cholesterol levels.

About Innovent

Founded in 2011, Innovent Biologics remains dedicated to developing high-quality biopharmaceuticals targeting critical diseases. Their commitment to meeting unmet medical needs has positioned them as a frontrunner in the biopharmaceutical industry, particularly concerning innovative treatments for cardiovascular and metabolic disorders.

With a current portfolio consisting of 20 launched products and ongoing research initiatives, Innovent emphasizes collaboration with industry experts to transition research advances into clinical applications effectively. Their motto, "Start with Integrity, Succeed through Action," reflects their commitment to enhancing patient outcomes through top-tier medical practices.

Conclusion

The recent results of Innovent’s SINTBILO™ serve as a beacon of hope in the landscape of hyperlipidemia treatment, highlighting a promising new option that addresses both efficacy and safety concerns. As the clinical landscape evolves, the arrival of SINTBILO™ could transform how hyperlipidemia is managed, offering individuals the potential for better lipid control and reduced cardiovascular risks.